Skip to content

Computerized Cognitive Remediation for Geriatric Depression

Computerized Cognitive Remediation for Geriatric Depression

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01979289
Enrollment
60
Registered
2013-11-08
Start date
2012-08-31
Completion date
2017-07-31
Last updated
2017-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder, Major Depressive Episode

Keywords

Executive Dysfunction, Cognitive Remediation, Geriatric, Depression

Brief summary

This research study will examine if a targeted computerized cognitive remediation (CCR) training program is better for treating geriatric depression than general computer activity. We will also examine whether this intervention is related to improvement in cognitive and depressive symptoms. Elderly patients with depression, who have, and who have not been treated with antidepressant medication for their illness, will be recruited to participate in either a 30 hour cognitive remediation program or general computer activity designed to be both challenging and interesting. They will be asked to complete between 1 and 3 hours of remediation per day over 4 weeks. While undergoing the cognitive remediation participants will be asked questions to assess their symptoms of, as well as the severity of, their depression weekly. This will inform researchers about whether or not the CCR is helping to improve depressive symptoms. At the end of the CCR study, participants will be given a battery of cognitive tests design to tell investigators whether or not the CCR improved their thinking in a variety of different ways including improving attention, memory, and organization. Investigators will also determine whether changes in participants' thinking are related to changes in their mood or other depressive symptoms. It is hoped that information gained from this study will help investigators to better understand the brain processes associated with depression, recovery from depression, and will help inform the development of future alternative treatments for this illness.

Interventions

OTHERcomputerized cognitive remediation:Control

Sponsors

Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

Medicated Depressed Participants' Inclusion Criteria 1. Age: 60-89 years 2. Diagnosis: Major depression, unipolar (by DSM-IV criteria); 3. Severity of depression: MADRS \>or =15 following at least 8-weeks of controlled antidepressant treatment. 4. No plans to change current antidepressant treatment. Non-Medicated Depressed Participants' Inclusion Criteria 1. Age: 60-89 years 2. Diagnosis: Major depression, unipolar (by DSM-IV criteria); 3. Severity of depression: MADRS \>or =15 4. No antidepressant treatment within the current episode. -

Exclusion criteria

1. Psychotic depression by DSM-IV, i.e., presence of delusions with a score higher than 2 (questionable delusion) rated by the Scale for Assessment of Positive Symptoms (SAPS) \[47\]; 2. High suicide risk, i.e. intent or plan to attempt suicide in near future; 3. Presence of any Axis I psychiatric disorder (other than unipolar major depression) or substance abuse; Axis II diagnosis of antisocial personality (by SCID-P and DSM-IV); 4. History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, and dysthymia are

Design outcomes

Primary

MeasureTime frameDescription
Montgomery-Asberg Depression Rating Scale4-6 weeks10 item measure to assess the core symptoms and cognitive features of clinical depression

Countries

United States

Contacts

Primary ContactMaria Coluccio, M.A.
914-997-4327
Backup ContactInstitute of Geriatric Psychiatry
914-997-4331

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026